Avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients with high-expression PD-L1+ metastatic non-small cell lung cancer: primary analysis from the phase 3 JAVELIN Lung 100 trial.
Fiche publication
Date publication
septembre 2023
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie
Tous les auteurs :
Reck M, Barlesi F, Chih-Hsin Yang J, Westeel V, Felip E, Özgüroğlu M, Cobo Dols M, Sullivan R, Kowalski DM, Andric Z, Ho Lee D, Sezer A, Hu P, Wang X, von Heydebreck A, Jacob N, Tadjalli Mehr K, Park K
Lien Pubmed
Résumé
We report the primary analysis from JAVELIN Lung 100, a phase 3 trial comparing avelumab (anti-PD-L1) vs platinum-based doublet chemotherapy as first-line treatment for PD-L1+ advanced non-small cell lung cancer (NSCLC).
Mots clés
avelumab, non-small cell lung cancer, phase 3
Référence
J Thorac Oncol. 2023 09 23;: